Search results
Jasper Therapeutics (JSPR) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks via Yahoo Finance· 2 months agoJasper Therapeutics (JSPR) made it through our "Recent Price Strength" screen and could be a great...
Jasper Therapeutics, Inc. (JSPR) Is Up 24.77% in One Week: What You Should Know
Zacks via Yahoo Finance· 2 months agoMomentum investing revolves around the idea of following a stock's recent trend in either direction....
Jasper (JSPR) Up on FDA Nod to Begin Early-Stage Urticaria Study
Zacks via Yahoo Finance· 7 months agoJasper (JSPR) announces the FDA clearance to begin the clinical study of briquilimab for chronic...
Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why
Zacks via Yahoo Finance· 4 months agoJasper Therapeutics (JSPR) surges after it provides business updates that highlight the company's...
Individual investors among Jasper Therapeutics, Inc.'s (NASDAQ:JSPR) largest shareholders, saw gain...
Simply Wall St. via Yahoo Finance· 1 year agoIf you want to know who really controls Jasper Therapeutics, Inc. (NASDAQ:JSPR), then you'll have to...
Jasper Therapeutics, Inc.'s (NASDAQ:JSPR) largest shareholders are retail investors with 42%...
Simply Wall St. via Yahoo Finance· 2 months agoKey Insights The considerable ownership by retail investors in Jasper Therapeutics indicates that...
All You Need to Know About Jasper Therapeutics, Inc. (JSPR) Rating Upgrade to Buy
Zacks via Yahoo Finance· 2 years agoJasper Therapeutics, Inc. (JSPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing...
Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans?
Simply Wall St. via Yahoo Finance· 4 months agoEven when a business is losing money, it's possible for shareholders to make money if they buy a...
Jasper Therapeutics Trade Higher As New Briquilimab Data Shows Safety, Efficacy In Blood Cancer...
Benzinga via Yahoo Finance· 1 year agoJasper Therapeutics Inc (NASDAQ: JSPR) announced that new data for briquilimab (formerly JSP191)...
Will Jasper Therapeutics (NASDAQ:JSPR) Spend Its Cash Wisely?
Simply Wall St. via Yahoo Finance· 1 year agoWe can readily understand why investors are attracted to unprofitable companies. For example,...